Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD
NCT05169021 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15000
Last updated 2021-12-23
Summary
The primary objectives of this trial are:
1. Efficacy evaluation of amlodipine folic acid tablets:
To assess the effects of amlodipine folic acid tablets 5.8 mg (5 mg amlodipine + 0.8 mg folic acid)versus amlodipine tablets 5 mg in preventing all-cause stroke in cerebral small vascular disease (CSVD) patients with hypertension and elevated homocysteine (Hcy) level.
2. Intensive Antihypertensive Therapy:
To assess the effect of intensive antihypertensive therapy (SBP\<130 mmHg) versus standard antihypertensive therapy (SBP 130-\<140 mmHg) in reducing risk of combined cardio-cerebrovascular events in CSVD patients with hypertension and elevated Hcy level, using two basic anti-hypertensive drugs, amlodipine tablets 5 mg or amlodipine folic acid tablets 5.8 mg.
Conditions
- Cerebral Small Vessel Diseases
- Stroke
Interventions
- DRUG
-
Amlodipine folic acid 5.8mg+intensive antihypertensive therapy
Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking. To achieve target blood pressure(SBP\<130mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below: 1. Add candesartan 4mg; 2. Add indapamide 2.5mg; 3. Increase dose of candesartan to 8mg; 4. Increase dose of amlodipine to 7.5mg-10mg.
- DRUG
-
Amlodipine folic acid 5.8mg+standard antihypertensive therapy
Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking. To achieve target blood pressure (SBP:130-140mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below: 1. Add candesartan 4mg; 2. Add indapamide 2.5mg; 3. Increase dose of candesartan to 8mg; 4. Increase dose of amlodipine to 7.5mg-10mg.
- DRUG
-
Amlodipine+intensive antihypertensive therapy
Amlodipine tablet 5.8mg, taken daily, in the morning after waking. To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below: 1. Add candesartan 4mg; 2. Add indapamide 2.5mg; 3. Increase dose of candesartan to 8mg; 4. Increase dose of amlodipine to 7.5mg-10mg.
- DRUG
-
Amlodipine+standard antihypertensive therapy
Amlodipine tablet 5.8mg, taken daily, in the morning after waking. To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below: 1. Add candesartan 4mg; 2. Add indapamide 2.5mg; 3. Increase dose of candesartan to 8mg; 4. Increase dose of amlodipine to 7.5mg-10mg.
Sponsors & Collaborators
-
Beijing Tiantan Hospital
lead OTHER
Principal Investigators
-
Yongjun Wang · Beijing Tiantan Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 35 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-12-31
- Primary Completion
- 2024-12-31
- Completion
- 2028-12-31
Countries
- China
Study Locations
More Related Trials
-
Efficacy and Safety Study of S-Amlodipine Gentisate Compared to Amlodipine Besylate to Treat Mild-to-Moderate Hypertension
NCT00289406 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension
NCT02969265 ·Status: WITHDRAWN ·Phase: PHASE3
-
Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes
NCT03264352 ·Status: RECRUITING ·Phase: PHASE4
-
The Effect of Losartan Versus Amlodipine-based Therapy in Ischemic Stroke (0954-338)(COMPLETED)
NCT00754429 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia
NCT03639480 ·Status: UNKNOWN ·Phase: PHASE3
-
Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function
NCT03082014 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension
NCT00425373 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients
NCT01011660 ·Status: UNKNOWN ·Phase: PHASE4
-
Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia
NCT03536598 ·Status: COMPLETED ·Phase: PHASE3
-
Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg
NCT01494727 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers
NCT02259803 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Confirm the Efficacy and Safety of Fixed-dose Combinations of Amlodipine and Candesartan
NCT03231982 ·Status: UNKNOWN ·Phase: PHASE4
-
Felodipine Event Reduction Study
NCT01136863 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients
NCT03946514 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension
NCT02944734 ·Status: COMPLETED ·Phase: PHASE2
-
Comparision of Blood Pressure Variability Between Amlodipine and Losartan
NCT01964079 ·Status: COMPLETED ·Phase: PHASE4
-
Fimasartan/Amlodipine Combination Phase III
NCT02152306 ·Status: COMPLETED ·Phase: PHASE3
-
Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients
NCT03015311 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine
NCT01663233 ·Status: COMPLETED ·Phase: PHASE3
-
Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation
NCT04111419 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Long Term Study Of Amlodipine 10mg With Hypertension For Whom Amlodipine 5mg Is Insufficient
NCT00443456 ·Status: COMPLETED ·Phase: PHASE3
-
A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient
NCT00415623 ·Status: COMPLETED ·Phase: PHASE3
-
An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ
NCT05413057 ·Status: RECRUITING
-
To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone
NCT01070043 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg
NCT01806311 ·Status: COMPLETED ·Phase: PHASE1